Update on emerging drugs for insomnia

Expert Opinion on Emerging Drugs

Volumn 17, Issue 3, 2012, Pages 295-298

  Sullivan, Shannon ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DORA; Hypnotics; Insomnia; Orexin

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALMOREXANT; DOPAMINE RECEPTOR AFFECTING AGENT; DOXEPIN; EPLIVANSERIN; EVT 201; HISTAMINE H1 RECEPTOR ANTAGONIST; ITI 007; LY 2624803; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; OREXIN A; OREXIN B; PALIPERIDONE; PIMAVANSERIN; SB 649868; SEROTONIN 2A ANTAGONIST; SUVOREXANT; TASIMELTEON; UNCLASSIFIED DRUG; ZOLPIDEM;

COGNITIVE THERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; LOW DRUG DOSE; NONREM SLEEP; PARKINSON DISEASE; REM SLEEP; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HISTAMINE ANTAGONISTS; HUMANS; HYPNOTICS AND SEDATIVES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; RECEPTORS, HISTAMINE; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84865603296     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.693158     Document Type: Review

References (17)

1. Sullivan SS, Guilleminault C. Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs 2009;14(3):411-22
2. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia and the performance of US workers: results from the America insomnia survey. Sleep 2011;34(9):1161-71
3. Sivertsen B, Lallukka T, Salo P. The economic burden of insomnia at the workplace. An opportunity and time for intervention? Sleep 2011;34(9):1151-2
4. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66
5. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13:150-5
6. Brisbare-Roch C, Clozel M, Jenck F. Effects of repeated oral administration of the orexin receptor antagonist almorexant in rats and dogs. Presented at SLEEP 2008, 22nd Annu. Meet. Assoc. Prof. Sleep Soc.; 7-12 June 2008; Baltimore, Md
7. Coleman P, Cox C, Breslin M, et al. Discovery of MK-4305: a novel orexin receptor antagonist for the treatment of insomnia. Presented at 239th ACS Natl. Meet; 21-25 March 2010; San Francisco
8. Dingemanse J, Dorffner G, Hajak G, et al. Proof-of-concept study in primary insomnia patients with almorexant (ACT-078573), a dual orexin receptor antagonist. Presented at WorldSleep07, 5th Int. Congr. World Fed. Sleep Res. Sleep Med. Soc.; 2-6 September 2007; Cairns, Aust
9. Coleman PJ, Schreier JD, Cox CD, et al. Discovery of [(2R,5R)-5-{[(5- Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2- yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 2012;7:415-24
10. Bettica P, Nucci G, Pyke C, et al. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol 2011;26:1058-70
11. Available from: http://www.merck.com/newsroom/news-release-archive/ researchand-development/2012-0206.html [Accessed 26 February 2012]
12. Available from: http://www.gsk.com/media/pressreleases/2011/2011- pressrelease-10019.htm
13. Unpublished Presented at World Association of Sleep Medicine Meeting; 10-15 September 2011; Quebec, CAN
14. Bettica P, Squassante L, Groeger JA, et al. Differential effects of a Dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012;37:1224-33
15. Available from: http://investors.somaxon. com/releasedetail.cfm? ReleaseID=655701
16. Available from: http://www.evotec.com/articles/en/Alliances-Projects/ Development-partnerships/4/6 [Accessed 24 January 2012]
17. Available from: http://ir.transcept.com/releasedetail.cfm?ReleaseID= 626494 [Accessed 15 April 2012]